The patient with the most durable response had normal karyotype NPM1/IDH2 mutated, FLT3-negative AML, and achieved a CRi after one cycle of induction and went on to receive fourteen cycles of maintenance chemotherapy. This evidence concerns the gene IDH2 and acute myeloid leukemia.